Patents by Inventor Christopher Rovaldi

Christopher Rovaldi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING ANEMIA
    Publication number: 20230142386
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate- 1 -risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Application
    Filed: September 14, 2022
    Publication date: May 11, 2023
    Applicant: Celgene Corporation
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
  • Activin-ActRII antagonists and uses for treating anemia
    Patent number: 11471510
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 18, 2022
    Assignees: CELGENE CORPORATION, ACCELERON PHARMA INC.
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING ANEMIA
    Publication number: 20170360887
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Application
    Filed: December 3, 2015
    Publication date: December 21, 2017
    Applicants: Celgene Corporation, Acceleron Pharma Inc.
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem